



## GoodRx Now Offers Access to Wegovy® HD at \$399 Per Month Self-Pay Price

April 15, 2026

*Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss*

### Brief Summary:

- Wegovy® HD is now available on GoodRx at a self-pay price of \$399 per month
- Pricing scales to \$798 for two-month supply and \$1,197 for three-month supply
- Available at pharmacies nationwide through GoodRx
- Consumers can determine eligibility and obtain a prescription through GoodRx for Weight Loss

SANTA MONICA, Calif.--(BUSINESS WIRE)--Apr. 15, 2026-- GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose [Wegovy® HD](#) (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at \$399 per month. Pricing scales with quantity, with a two-month supply available for \$798 and a three-month supply available for \$1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an additional FDA-approved step-up option within the Wegovy portfolio, potentially helping eligible patients achieve greater weight-loss benefit without requiring them to switch to a different brand or care pathway.

"Pharmaceutical innovation is moving quickly to meet the evolving needs of patients, and access has to keep pace," said Wendy Barnes, President & CEO at GoodRx. "Wegovy HD is a strong example of how manufacturers are expanding options to support patients at different stages of treatment. GoodRx is proud to help translate that innovation into real-world access, connecting patients to the FDA-approved therapies and dosing they need with clear, predictable pricing."

As demand for GLP-1 treatments continues to grow, many consumers are navigating access outside of traditional insurance coverage. GoodRx simplifies that experience by surfacing upfront pricing and connecting it directly to nationwide pharmacy access, helping consumers understand their options before they reach the pharmacy counter.

"We're continuing to expand the Wegovy® portfolio with a simple goal: give patients the right option at the right time in their treatment," said Ed Cinca senior vice president, Marketing & Patient Solutions at Novo Nordisk. "Wegovy® HD adds another FDA-approved option to meet patients' clinical needs. Working with GoodRx helps make these medicines easier to access for the people who need them."

For those who need help getting started, [GoodRx for Weight Loss](#) offers a connected path to care. Through the subscription service, consumers can meet with licensed healthcare providers, complete an eligibility assessment, and, when appropriate, receive a prescription for FDA-approved GLP-1 treatments.

This announcement builds on GoodRx's ongoing efforts to expand access to GLP-1 medications, reflecting a broader shift toward self-pay models that provide more predictable and transparent pathways to treatment. GoodRx enables these programs to reach consumers at scale, helping ensure that pricing translates into real-world access from day-one.

### **About GoodRx**

GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over \$100 billion on the cost of their medications.

*GoodRx periodically posts information that may be important to investors on its investor relations website at <https://investors.goodrx.com>. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.*

### **GoodRx Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our offerings to consumers, GoodRx, Novo Nordisk, and other pharmaceutical manufacturers; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors

discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260415441592/en/): <https://www.businesswire.com/news/home/20260415441592/en/>

**Media Contact**

[press@goodrx.com](mailto:press@goodrx.com)

Source: GoodRx